Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / FOLD - Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease | Benzinga

FOLD - Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease | Benzinga

Amicus Therapeutics Inc.

The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease.

It's a disease in which the body can't make a protein that breaks down a complex sugar called glycogen for energy. Too much sugar builds up and damages muscles and organs.

This two-component therapy is indicated for adults living with late-onset ...

Full story available on Benzinga.com
Stock Information
Company Name: Amicus Therapeutics Inc.
Stock Symbol: FOLD
Market: NASDAQ
Website: amicusrx.com
Menu
FOLD FOLD Quote FOLD Short FOLD News FOLD Articles FOLD Message Board
Get FOLD Alerts

News, Short Squeeze, Breakout and More Instantly...